Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative. We show here that cell lines expressing JAK2(V617F), MPL(W5...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Nieborowska-Skorska, Margaret, Maifrede, Silvia, Dasgupta, Yashodhara, Sullivan, Katherine, Flis, Sylwia, Le, Bac Viet, Solecka, Martyna, Belyaeva, Elizaveta A., Kubovcakova, Lucia, Nawrocki, Morgan, Kirschner, Martin, Zhao, Huaqing, Prchal, Josef T., Piwocka, Katarzyna, Moliterno, Alison R., Wasik, Mariusz, Koschmieder, Steffen, Green, Tony R., Skoda, Radek C., Skorski, Tomasz
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746670/
https://ncbi.nlm.nih.gov/pubmed/29042365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-784942
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados